Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | Mutations in ALL and their implications for treatment decisions

Kjeld Schmiegelow • 28 Sep 2022
SOHO 2022
Acute Lymphoblastic Leukemia Leukemia

Kjeld Schmiegelow, MD, Rigshospitalet University Hospital, Copenhagen, Denmark, emphasizes the importance of evaluating the risk associated with specific cytogenetic aberrations in acute lymphoblastic leukemia (ALL) in the context of different therapies and their impact on these patient groups. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Kjeld Schmiegelow

3:11
Key findings from the NOPHO ALL2008 experience: advances in ALL diagnosis and treatment
Kjeld Schmiegelow • 28 Sep 2022
2:27
The importance of monitoring metabolites during maintenance therapy in ALL
Kjeld Schmiegelow • 28 Sep 2022
2:15
Diagnosing & managing CNS disease in patients with ALL
Kjeld Schmiegelow • 28 Sep 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals